Does Rallies show 13F holders for TMDX?

Yes. Rallies tracks hedge fund and 13F ownership data for TMDX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TMDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TMDX. It does not provide personalized investment advice.

TMDX (TransMedics) Stock Analysis - Hedge Fund Holdings

TransMedics (TMDX) is a publicly traded Healthcare sector company. As of May 21, 2026, TMDX trades at $68.94 with a market cap of $2.36B and a P/E ratio of 13.62. TMDX moved +2.92% today. Year to date, TMDX is -46.15%; over the trailing twelve months it is -45.47%. Its 52-week range spans $55.00 to $160.80. Analyst consensus is buy with an average price target of $130.80. Rallies surfaces TMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TMDX stock?

Hedge funds tracked by Rallies that own TMDX include Davidson Kempner, Bridgewater Associates, Panagora Asset, Eisler Capital, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TransMedics.

TMDX Key Metrics

Key financial metrics for TMDX
Metric	Value
Price	$68.94
Market Cap	$2.36B
P/E Ratio	13.62
EPS	$5.05
Dividend Yield	0.00%
52-Week High	$160.80
52-Week Low	$55.00
Volume	1.72K
Avg Volume	0
Revenue (TTM)	$635.89M
Net Income	$171.92M
Gross Margin	59.09%

Top Hedge Funds Holding TMDX

Davidson Kempner holds 146.40K shares of TMDX, changed +0.00% as of Mar 31, 2026.
Bridgewater Associates holds 30.09K shares of TMDX, changed +768.76% as of Sep 30, 2025.
Panagora Asset holds 22.58K shares of TMDX, changed -77.86% as of Mar 31, 2026.
Eisler Capital holds 9.66K shares of TMDX, changed +0.00% as of Mar 31, 2024.
Polen Capital holds 7.42K shares of TMDX, changed -31.46% as of Mar 31, 2026.

Latest TMDX News

TransMedics Reports Double-Digit Q1 Revenue Growth, Confirms Full-Year Guidance — May 8, 2026
TransMedics Q1 Revenue Climbs 21% to $173.9M, Unveils CHOPS, European Push — May 5, 2026
TransMedics Invests in PAD Aviation to Build European Organ Transplant Air Logistics Network — Apr 29, 2026
TransMedics Unveils CHOPS to Back OCS ENHANCE Heart and DENOVO Lung Trials — Apr 23, 2026
TransMedics Reports Jump in Q4 Profit, Shares Climb — Feb 25, 2026

Recent TMDX Insider Trades

Lovell Stephanie sold 1.19K (~$178.50K) on Mar 4, 2026.
Weill David sold 3.57K (~$524.29K) on Mar 4, 2026.
Hernandez Gerardo sold 1.32K (~$194.91K) on Mar 4, 2026.

TMDX Analyst Consensus

11 analysts cover TMDX: 0 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $130.80.

Common questions about TMDX

Who owns TMDX stock?: Hedge funds tracked by Rallies that own TMDX include Davidson Kempner, Bridgewater Associates, Panagora Asset, Eisler Capital, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TransMedics.
Does Rallies show 13F holders for TMDX?: Yes. Rallies tracks hedge fund and 13F ownership data for TMDX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TMDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TMDX. It does not provide personalized investment advice.